| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Būtiski notikumi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2007-10-10 13:17:50 |
| Versijas komentārs | |
| Teksts |
Today, 9th October during the third meeting of the Latvian-Byelorussian Inter-Governmental Commission on Economic, Scientific and Technical Cooperation a notice of intention was signed between JSC “Grindeks”, the leading Byelorussian Pharmaceutical Company RUE “Borisov Medical Preparations Plant” and Byelorussian State Production and Sales Holding of Pharmaceutical and Microbiological Products „Belbiofarm” about the cooperation in the implementation of the investment project “Building of new department for production of finale dosage forms”. „I am satisfied with the today concluded notice of intention that foresees a possible cooperation between Grindeks and the leading Byelorussian pharmaceutical producer allowing to secure Grindeks positions in the markets of Russia and other CIS countries in the future”, expressed Chairman of the Board of JSC “Grindeks” Jānis Romanovskis. Representative office of Grindeks in Belarus is working since 2002. Sales amount of the final dosage forms in this country increases every year, and during the first 6 months of 2007 it comprised 5.7% of the total final dosage forms sales amount. JSC “Grindeks” is the leading pharmaceutical company in the Baltic States, specializing in the manufacturing of heart and cardiovascular medications; CNS drugs and anti-cancer agents. Its concern consists of four subsidiary companies in Latvia, Estonia and Russia and ten representative offices. Grindeks` production is exported to 40 countries. Main sales markets are: Baltic States, Russia, and CIS countries, Japan, USA. Grindeks shares are listed in the Official list of Riga Stock Exchange. Ilze Kreicmane Deputy Manager of the Communications Department JSC “Grindeks” Phones: 67083336, 26466681 ilze.kreicmane@grindeks.lv |
| Pielikumi |
|